A number of antitumor vaccines have recently shown promise in upregulating immune responses against tumor antigens and improving patient survival. In this study, we examine the effectiveness of vaccination using interleukin (IL)-15-expressing tumor cells and also examine their ability to upregulate immune responses to tumor antigens. We demonstrated that the coexpression of IL-15 with its receptor, IL-15Ra, increased the cell-surface expression and secretion of IL-15. We show that a gene transfer approach using recombinant adenovirus to express IL-15 and IL-15Ra in murine TRAMP-C2 prostate or TS/A breast tumors induced antitumor immune responses. 
INTRODUCTION
Tumor cell vaccines have shown preclinical promise and antitumor activity in patient trials in a number of malignancies, including breast, prostate and pancreatic cancer, and leukemia (reviewed in Keenan and Jaffee 1 ). These vaccines have the advantage over single-antigen vaccines in that they can target multiple known and unknown tumor-associated antigens. The whole tumor cell vaccine platform that has been the furthest developed is GVAX (granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine), which consists of irradiated autologous or allogeneic tumor cells genetically modified to secrete granulocyte-macrophage colony-stimulating factor. GVAX has been shown to induce the infiltration of dendritic cells to the vaccination site, and stimulate CD8 þ and CD4 þ T-cell responses, as well as antibody responses (reviewed in Eager and Nemunaitis 2 ). The clinical outcomes of phase III trials of GVAX, however, have been disappointing. Two randomized, controlled phase III trials of GVAX in prostate cancer (VITAL-1 and VITAL-2) were terminated owing to a lack of efficacy compared with standard chemotherapy with docetaxel and prednisone. 3, 4 In the VITAL-2 study, an increase in patient deaths was also noted in the GVAX arm.
Interleukin-15 (IL-15) is a proinflammatory cytokine capable of stimulating the differentiation and proliferation of T, B and natural killer (NK) cells. It is essential for the differentiation and maintenance of memory CD8 þ T cells and NK/T cells. 5 It can also promote the development of dendritic cells. 6 IL-15 function is mediated through its heterotrimeric receptor composed of IL-15Ra, IL-2R/IL-15Rb (CD122), and the common cytokine receptor g-chain (gc, CD132). 7, 8 IL-15 is tightly bound by IL-15Ra alone, anchoring it on the surface of antigen-presenting cells and limiting its secretion. Signaling is initiated by presentation of IL-15 by IL-15Ra in 'trans' to the IL-2R/IL-15Rb and gc expressed on the effector cells. 9 The coexpression of IL-15 and IL-15Ra on nonlymphoid cells such as antigen-presenting cells has been shown to be necessary to support its 'trans' presentation and activation of effector cells. 10 In HIV infection, the coordinated dysregulation of IL-15 and IL-15Ra has been shown to occur in progressive disease underlying the importance of coexpressing IL-15 and IL-15Ra. 11 We utilized IL-15 to develop a whole-tumor cell vaccine targeting murine breast and prostate cancer. We show that tumor cells transduced with IL-15 inhibited tumor growth in vivo and this was enhanced when IL-15Ra was also coexpressed by the tumor cells. Vaccination with modified tumor cells expressing IL-15 and IL-15Ra inhibited tumor formation and led to increased survival. Furthermore, we show that the immune responses induced by vaccination are mediated by CD8 þ T cells and NK cells. Figure 1c ). The media retained its ability to induce CTLL-2 proliferation to a dilution of 1:1000. In order to determine the cellular localization of IL-15 following transduction with Ad.mIL-15, Ad.null or Ad.mIL-15 þ Ad.mIL-15Ra, we examined transduced TS/A tumors by immunohistochemistry. TS/A tumors that had been infected with Ad.null did not exhibit any IL-15 staining, whereas those transduced with either Ad.mIL-15 alone or in combination with Ad.mIL-15Ra showed significant IL-15 staining (Figures 1d-f) . TS/A cells transduced with Ad.mIL-15 alone expressed IL-15 throughout the cell, whereas those that had been transduced with both Ad.mIL-15 and Ad.mIL-15Ra exhibited IL-15 staining predominantly at the surface of the cell.
RESULTS

Tramp
TRAMP-C2 and TS/A cells expressing IL-15 and IL-15Ra significantly inhibited tumor growth In order to examine the effects of IL-15 and IL-15Ra expression on tumor growth we transduced TS/A and TRAMP-C2 cells with Ad.mIL-15 with or without Ad.mIL-15Ra and subcutaneously injected them into syngeneic BALB/c or C57Bl/6 mice, respectively. We found that the expression of IL-15 alone or in combination with IL-15Ra inhibited the growth of TS/A (Figure 2a ) and TRAMP-C2 tumors (Figure 2b ) (Po0.05). In both tumor lines, the added expression of IL-15Ra further inhibited tumor growth when compared with IL-15 alone. IL-15Ra alone also reduced tumor growth in TS/A (Po0.05).
To further show that IL-15 expression by tumors could inhibit tumor growth, we injected Ad.mIL-15, Ad.mIL-15Ra, Ad.mIL-15 þ Ad.mIL-15Ra or Ad.null into actively growing TS/A or TRAMP-C2 tumors in vivo. Ad.mIL-15 or Ad.mIL-15 þ Ad.mIL-15Ra resulted in significant tumor growth reduction when compared with Ad.null þ T-cell infiltrates, we found no differences in the relative numbers of these cells in either TRAMP-C2 or TS/A tumors.
Vaccination with TRAMP-C2 or TS/A cells expressing IL-15 and IL-15Ra induces cell-mediated immune responses
In order to assess the tumor-specific effects of the vaccine, we examined the ability of splenocytes from TRAMP-C2-and TS/A-vaccinated mice to lyse the respective unmodified tumor cells ex vivo. After stimulation with tumor antigens, splenic cells isolated from TRAMP-C2-Ad.null-treated mice demonstrated little lytic activity against TRAMP-C2 or MC38 cells (Figure 6a ), whereas spleen cells isolated from TRAMP-C2-IL-15/IL-15Ra showed increased lytic activity against TRAMP-C2 cells, but not against murine MC38 colon cancer. Similarly, splenocytes isolated from TS/A-Ad.null-treated mice showed little lytic activity, whereas those isolated from TS/A-IL-15/IL-15Ra showed increased lytic activity against TS/A and TUBO cells, indicating a tumor-specific immune response (Figure 6b ). Greater lytic activity was shown against TS/A cells as compared with TUBO cells. To confirm that the lytic activity seen was directed against the CD8-immunodominant tumor antigens, we assessed the ability of splenocytes from animals vaccinated with TRAMP-C2 or TS/A expressing IL-15/IL-15Ra or an Ad.null to secrete interferon (IFN)-g in response to SNC9-H8, a CD8-restricted TRAMP-C2 immunodominant peptide, or AH1, a CD8-restricted TS/A immunodominant peptide. Splenocytes from mice vaccinated with either TRAMP-C2 or TS/A cells expressing IL-15/IL-15Ra secreted significantly more IFN-g than those isolated from mice vaccinated with TRAMP-C2 or TS/A expressing Ad.null when exposed to SNC9-H8 or AH1, respectively (Po0.01) (Figures 6c and d) . No IFN-g release was seen when exposed to OVA or p66, whereas IFN-g was released from splenocytes of the IL-15/IL-15Ra or Ad.null-treated animals exposed to HEX486-494 or DBP43, immunodominant epitopes of adenovirus. In addition to increased lytic activity or IFN-g release, animals vaccinated with TRAMP-C2 expressing IL-15/IL-15Ra had more SPAS-1 tetramer-specific CD8 þ cells (Figure 6e ) compared with those vaccinated with TRAMP-C2 cells transduced with Ad.Null (Figure 6f ), or untreated animals (data not shown).
DISCUSSION IL-15 is a powerful proinflammatory cytokine that can enhance innate and adaptive immune responses (reviewed in Steel et al. 12 ). Recently, recombinant human IL-15 has entered clinical trials for treatment of patients with metastatic melanoma and renal cell carcinoma. 13 In preclinical studies, IL-15 has been shown to be active as a single agent or in combination with other immune-modulating agents, such as anti-CD40, anti-PD-L1 and anti-CTLA-4. [14] [15] [16] Due to its immunostimulatory effects, IL-15 is also being studied as a vaccine adjuvant. [17] [18] [19] We and others demonstrated that the coexpression of IL-15 along with its receptor, IL-15Ra, as a vaccine, enhanced the biological activity of IL-15. [20] [21] [22] [23] Here we showed that murine TS/A and TRAMP-C2 tumor cells can be transduced with adenoviruses expressing IL-15 and IL-15Ra, and that the cells secrete functional IL-15. Bergamaschi et al. 24, 25 reported that IL-15 and IL-15Ra bind intracellularly and that this interaction stabilizes the protein, allowing IL-15 to be secreted, whereas when IL-15 is expressed in the absence of IL-15Ra it is rapidly degraded, allowing only limited amounts to be secreted. In line with this, we showed that TS/A and TRAMP-C2 cells expressing both IL-15 and IL-15Ra secreted greater quantities of IL-15 than those cells that expressed IL-15 alone.
In humans, very little IL-15 is detected in the serum; rather IL-15 is predominantly found on the surface of cells bound to its receptor. Most IL-15 detected in the blood is thought to be bound to soluble IL-15Ra cleaved from the surface of cells. IL-15Ra has been shown to trans-present the cytokine to effector cells. 9 The trans-presentation of IL-15 by IL-15Ra is the primary way in which IL-15 signals through the b-and g-chains of the IL-15 receptor, and both IL-15 and IL-15Ra are required to be expressed by the same cell to allow trans-presentation to occur. 10, 26 This complex signaling mechanism may act to regulate the effects of IL-15 by allowing tightly controlled and directed delivery to the effector cells (reviewed in Stonier and Schluns 27 ) . From this, we posited that the coexpression of IL-15 and IL-15Ra on tumor cells would allow the surface trans-presentation by the tumor cells to effector cells to stimulate an antitumor response. We found that coexpressing IL-15 with IL-15Ra led to IL-15 expression on the surface of the tumor cells, whereas the expression of IL-15 alone showed diffuse cytoplasmic localization within the cells (Figure 1) . The requirement for IL-15Ra for the cell surface expression of IL-15 is supported by Bergamaschi et al., 25 who showed that little IL-15 is detected on the cell surface following the transfection with a plasmid expressing IL-15 alone, whereas when they combined IL-15 with IL-15Ra they were able to detect IL-15 expression on the surface of the cells.
In terms of function, we showed that coexpression of IL-15 and IL-15Ra in TS/A breast or TRAMP-C2 prostate cancer cells resulted in smaller tumors than when the cells expressed IL-15 alone. These effects were seen when the tumor cells were transduced with IL-15 and IL-15Ra prior to implantation or when IL-15 and IL-15Ra was delivered into pre-established tumors. A number of studies have shown that gene delivery of IL-15 into tumor cells can induce an antitumor response. [28] [29] [30] [31] In this study, we showed that tumor cells transduced with IL-15 alone did have an antitumor effect when compared with the Ad.null control; however, this was significantly less than that seen when IL-15 was combined with IL-15Ra.
IL-15 has been reported to induce tumor-cell killing through the stimulation of NK and CD8 þ T cells (reviewed in Steel et al. 12 ). We showed that the depletion of NK cells and CD8 þ lymphocytes limited the antitumor effect of treatment with IL-15 and its receptor, providing evidence that in our models NK and CD8 þ T cells have an essential role. This is in line with the results shown by Dubois et al. 32 using soluble IL-15/IL-15Ra-IgG1-Fc complexes. The ability of IL-15 and its receptor to induce a CD8 þ T-cell response directed against the tumor following the transduction of the tumor cells with IL-15 and IL-15Ra pointed at this combination's potential to be used as a vaccine. Genetically modified tumor cell vaccines such as GVAX, engineered to express granulocyte-macrophage colony-stimulating factor, that demonstrated activity in early clinical trials 1,2 have failed to show efficacy in phase III trials. 3, 4 Further, in the GVAX phase III trial comparing GVAX and docetaxel to docetaxel and prednisone, there was greater risk of death associated with the vaccine þ , CD8 þ and NK cells were depleted from the mice using injections of 200 mg of anti-CD4 (GK1.5) or anti-CD8 (2.43) or 50 mg of anti-NK (anti-asialo GM1) antibodies as described in Materials and methods. Mice were followed for tumor growth (10 mice per group). Error bars ¼ s.e.m.
treatment. The strong proinflammatory characteristics of IL-15 and the predominantly cell-bound nature of IL-15, when combined with IL-15Ra, and its requirement of trans-presentation for effector cell activation may allow IL-15/IL-15Ra-expressing tumor cells to induce a safer, more targeted immune response than previously studied tumor vaccines.
To examine the efficacy of a IL-15/IL-15Ra-expressing tumor cell vaccine, we transduced mouse TS/A breast cancer or TRAMP-C2 prostate cancer cells with Ad.IL-15 and Ad.IL-15Ra, and used these cells as a vaccine. We showed that this vaccine stimulated an antitumor immune response leading to a significant prolongation of survival when animals were challenged with TS/A or TRAMP-C2 cells. Tumors isolated from these animals had greater levels of 33 This may broaden the antitumor response allowing shared subdominant tumor antigens to be targeted, thereby increasing the potential for success when using IL-15 and IL-15Ra to augment allogeneic vaccinations. In addition, the use of whole tumor cells as the base of this vaccine allows the potential targeting of multiple uncharacterized tumor antigens, unlike other vaccine strategies such as genetically engineered dendritic cells 21 or viral vaccines 18 where specific antigens must be identified in the tumor and vectors designed around those antigens.
We also showed that IL-15/IL-15Ra-expressing tumor vaccines are effective in a clinically relevant therapeutic setting. Mice harboring poorly immunogenic and highly aggressive TS/A tumors could be effectively treated with IL-15/IL-15Ra-expressing tumor vaccines, leading to a significant prolongation of survival. 
MATERIALS AND METHODS
Cell lines
TS/A and TUBO mouse mammary carcinoma cell lines were derived from a BALB/c background and were gifts from Dr Patrizia Nanni (University of Bologna, Bologna, Italy) 34, 35 and were grown in Dulbecco's modified Eagle medium (DMEM, BioSource, Gaithersburg, MD, USA) with 10% fetal bovine serum (FBS; Gemini, Calabassas, CA, USA) and 10 mg ml À 1 gentamicin sulfate (BioSource). Human embryonic kidney (HEK-293) cells and murine TRAMP-C2 prostate cancer cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were grown in DMEM with 10% FBS and 10 mg ml À 1 gentamicin sulfate (BioSource). MC38 murine colon cancer cells were grown in DMEM with 10% FBS and 10 mg ml À 1 gentamicin sulfate (BioSource). TRAMP-C2 and MC38 cells were derived on a C57Bl/6 background. CTLL-2 cytotoxic T cells were purchased from the American Type Culture Collection (ATCC) and were cultured in RPMI 1640 supplemented with 10% FBS and 200 U ml À 1 IL-2.
Adenoviruses
The murine IL-15 and IL-15Ra cDNAs 34 were provided by Dr Yutaka Tagaya (National Cancer Institute, Bethesda, MD, USA). Ad.mIL-15 and Ad.mIL-15Ra are E1, E3-deleted recombinant adenoviruses (rAd) expressing the murine IL-15 and IL-15Ra, respectively. Ad.null is an E1, E3-deleted rAd control vector expressing no transgene. All vectors were generated using the AdMax system (Microbix Biosystems, Mississaugua, ON, Canada), 36 40 and OVA257-264 (SIINFEKL), an epitope from hen ovalbumin, 40 were purchased from Genscript (Piscataway, NJ, USA).
Animals
Male 6-8-week-old C57Bl/6 mice and female 6-8-week-old BALB/c mice were obtained from the Division of Cancer Research and Treatment, National Cancer Institute (NCI; Frederick, MD, USA). All the animals were maintained in the NCI animal holding facility and their use adhered to the NIH Laboratory Animal Care Guidelines and was approved by the NCI Animal Care and Use Committee.
Flow cytometry SPAS-1 tetramer was previously described.
14 Cell surface expression of CD8, CD4 and CD94 was performed using antibodies from eBioscience (San Diego, CA, USA) and analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA).
IL-15 secretion and activity
Culture supernatants were removed before and 48 h after infection of tumor cells with Ad.mIL-15 þ Ad.mIL-15Ra or Ad.null, each at a multiplicity of infection (MOI) of 100. Supernatants were assayed for murine IL-15 by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. To assess the functionality of secreted IL-15, supernatants were diluted and incubated with CTLL-2 cells. 41 Ad.mIL-15Ra or Ad.null at 1 Â 10 9 plaque-forming unit. Mice were evaluated daily to assess tumor growth. Tumor volumes were calculated using the formula: tumor volume ¼ (l Â w) 2 /2.
Immune cell depletion
Groups of BALB/c mice were depleted of specific immune cell populations. 21 Briefly, CD4 þ or CD8 þ cells were depleted with anti-CD4 or anti-CD8 antibodies purified from the supernatants of hybridomas GK1.5 (ATCC) and 2.43 (ATCC), respectively. Five days before vaccination with TS/A transduced with IL-15, IL-15 þ IL-15Ra or Ad.null, mice were intraperitoneally injected with 200 mg of the appropriate antibody for three consecutive days and continued every 3 days thereafter for the duration of the experiment. To deplete NK cells, anti-asialo GM1 50 mg (WAKO, Richmond, VA, USA) was administered beginning 5 days before tumor implantation for three consecutive days and then continued every 3 days thereafter. Greater than 95% depletion of specific lymphocyte populations was confirmed by peripheral blood flow cytometry. 
